Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: smahi who wrote (58004)	3/14/2007 1:02:31 PM
From: Henrik	Respond to of 59879

I'll leave it to Mark to reply with a TA view, but from a FA point it is time to get set for the next spike. If not sooner this spike is likely to take place when fresh and very promising data is being presented in US and in Spain next month. The company announcement below was not reported widely in the US media. Go back and have a look at the Dec. 2006 spike caused by the 30 weeks liver data. A repeat of this may very well be in the making now that the are presenting survival rates based on up to 48 week data. Also, Progen’s profile among US brokers will be enhanced in the near future by the appointment of a new US based PR company. Disclosure: I hold PGLA. --------------------------------------------------------- PI-88 Data to be Presented at Key International Conferences. Brisbane, Australia. 12 March 2007: Progen Industries Limited (ASX: PGL; NASDAQ: PGLA)is pleased to announce that its PI-88 Phase II liver cancer data has been accepted for late breaking news presentation by the European Association for the Study of the Liver (EASL). Progen will also be presenting the results of this liver cancer trial at the American Association for Cancer Research (AACR) Annual Meeting 2007. In expectation of having final data fully analysed and ready for disclosure, Progen is planning for Professor PJ Chen, Principal Investigator of this trial, to present the 48 week data for all 172 patients that were recruited to this multi-site Phase II clinical trial. This presentation will take place on Saturday 14 April 2007 at the 42nd EASL Annual Meeting, which is to be held in Barcelona, Spain from April 11-15, 2007. Dr. Anand Gautam, Progen’s VP of Discovery Research, will be presenting results at the AACR Annual Meeting 2007, which will be held in Los Angeles, U.S, from April 14-18, 2007.